biontech se’s stock bntx rose 43 in premarket trade monday after the german biotech posted far strongerthanexpected firstquarter earnings even as profit and revenue tumbled on lower demand for its covid vaccine codeveloped with pfizer inc pfe mainzbased biontech said it had net profit of 5022 million euros or 205 a share for the quarter down from eur3699 billion or eur1424 a share in the yearearlier period revenue fell to eur1277 billion from eur6375 billion the factset consensus was for eps of 27 cents and revenue of eur1061 billion the company is still expecting eur5 billion of covid revenue